Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intestifix
- Development stage
- Unknown
- Lead developer
- Goethe-Universität Frankfurt
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Intestifix is a live biotherapeutic product (LBP) developed by researchers at Goethe University Frankfurt, specifically designed for the decolonization of multidrug-resistant Enterobacteriaceae (MDR-E) from the human gastrointestinal tract. It consists of a defined consortium of commensal bacterial strains, offering a standardized and characterized alternative to fecal microbiota transplantation (FMT). The product aims to restore a healthy intestinal microbiome and eliminate resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and ESBL-producing strains, through competitive exclusion and other ecological interactions. By suppressing these resistant organisms, Intestifix seeks to reduce the risk of endogenous infections and the transmission of multidrug-resistant bacteria in clinical settings. It is currently being investigated in Phase 1/2 clinical trials.
- Brand names
- Intestifix
- Other names
- Defined Microbiota ProductDMP
Beyond the preview
Go deeper on Intestifix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intestifix.